Polonium and Lung Cancer

The alpha-radioactive polonium 210 (Po-210) is one of the most powerful carcinogenic agents of tobacco smoke and is responsible for the histotype shift of lung cancer from squamous cell type to adenocarcinoma. According to several studies, the principal source of Po-210 is the fertilizers used in tobacco plants, which are rich in polyphosphates containing radio (Ra-226) and its decay products, lead 210 (Pb-210) and Po-210. Tobacco leaves accumulate Pb-210 and Po-210 through their trichomes, and Pb-210 decays into Po-210 over time. With the combustion of the cigarette smoke becomes radioactive and Pb-210 and Po-210 reach the bronchopulmonary apparatus, especially in bifurcations of segmental bronchi. In this place, combined with other agents, it will manifest its carcinogenic activity, especially in patients with compromised mucous-ciliary clearance. Various studies have confirmed that the radiological risk from Po-210 in a smoker of 20 cigarettes per day for a year is equivalent to the one deriving from 300 chest X-rays, with an autonomous oncogenic capability of 4 lung cancers per 10000 smokers. Po-210 can also be found in passive smoke, since part of Po-210 spreads in the surrounding environment during tobacco combustion. Tobacco manufacturers have been aware of the alpha-radioactivity presence in tobacco smoke since the sixties

COVID-19, a syndemic well before a pandemic disease! The role of tobacco smoking

n/

Why universities and scientific world should stay away from the tobacco industry. Journey in Big Tobacco deception

Universities are institutions dedicated to improving life through the research and dissemination of knowledge. They facilitates the "peer to peer" communication among young people; the acquisition of knowledge and skills to improve personal and community health; the propagation of healthy lifestyles through the emulation of behavior. Tobacco industry, through commercial policies, enlist young people and transform them, through dependence, into "loyal customers" for many years. The recent introduction of the "reduced risk" products, (the so-called "cold smoke" for example), are a threat for young people who might underestimate the dangers, not even completely known by the experts. Universities and Scientific world that turn a blind eye to tobacco market, accepting the advantages offered by grants and donations from tobacco industry, become accomplices in spreading the "tobacco epidemic" because the funding comes directly from the sale of tobacco products. This "dirty" money causes illness, suffering and death. Universities are invested with an important ethical responsibility to help the world reduce and eliminate the tobacco epidemic, with research, training and information. Universities should have a policy statement that specifically prohibits academic bodies from accepting tobacco industry funding including grant funding. In the U.S.A. several scientific journals no longer publish tobacco industry- supported researches

The “polonium in vivo” study. Polonium-210 in bronchial lavages of patients with suspected lung cancer

Few studies have reported on polonium-210, a decay breakdown product of radon-222 and lead-210, in human lungs and there has been no study in patients with suspected lung cancer. The main aim of this "Polonium in vivo" study was to evaluate polonium-210 radioactivity in bronchopulmonary systems of smoker, ex-smoker and never smoker patients with suspected lung cancer. Alpha-spectrometric analyses were performed on bronchial lavage (BL) fluids from two Italian hospitals in 2013-2016. Socio-demographic, smoking, occupational and spirometric characteristics, lung cancer confirmation and histologic type and radon-222 concentration in patients' homes were collected. Seventy BL samples from never (n = 13), former (n = 35) and current smokers (n = 22) were analyzed; polonium-210 was detected in all samples from current and former smokers and in 54% of samples from never smokers (p < 0.001; median values: 1.20, 1.43 and 0.40 mBq, respectively). Polonium-210 levels were significantly higher in COPD versus no COPD patients (median value: 3.60 vs. 0.97 mBq; p = 0.007); former and current smokers, without and with COPD, had significantly increased polonium-210 levels (p = 0.012); 96% of confirmed versus 69% of non-confirmed lung cancer patients recorded detectable polonium-210 levels (p = 0.018). A polonium-210 detectable activity was measured in BL samples from all current and former smokers. Polonium-210 in the lungs could be the result of lead-210 entrapment, which, with its half-life of 22 years, could provide a continuous emission of alpha radioactivity, even many years after quitting, thus proposing a possible explanation for the onset of lung cancer, particularly in former smokers

Influence of tobacco smoking on farmacological medication

Cigarette smoke, that contains more than 4.000 substances, may directly or indirectly influences the efficacy and the tolerability of many medications through complex pharmacokinetic and pharmacodinamic interactions. In fact, cigarette smoke, and in particular polycyclic aromatic hydrocarbons, nicotine, carbon monoxide and heavy metals, powerful enzymatic inducers, determines modifications of the sistemic and local bioavailability of several drugs. Therefore, in patients who are currently assuming any therapy, the clinicians should consider adjustments of dosages either when a smoker patient starts a new drug or when he quits smoking. The purpose of this review is to examine the main drug interactions with tobacco smoke clinically relevant that can be of particular importance especially in patients with multiple comorbidities, with a closer look on those who developed respiratory, cardiovascular, oncologic or psychiatric diseases